W 1645

ractitioner's Docket No. U 016156-3

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

nt application

Inventor(s)

for

Title of invention

OR

In re application of:

GERRIT DIRK KEIZER, et al

Serial No.: 10/568,633

Filed: October 26, 2006 Group No.: 1645 N/A Examiner:

METHOD FOR DETECTING MULTIPLE ANALYTES

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Date: January

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10* (When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

transmitted by facsimile to the Patent and Trademark Office.

37 C.F.R. 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee" (mandatory) Mailing Label No.

(type or print name of person certifying)

TRANSMISSION

Janet I. Cord

Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

(1)	Each U.S. patent listed in an information disclosure statement must be identified by inventor, patent number, and issue date.
(2)	Each U.S. patent application published listed in an information disclosure statement shall be identified by applicant, patent application publication number, and publication date.
(3)	Each U.S. application listed in an information disclosure statement must be identified by the inventor, application number, and filing date.
(4)	Each foreign patent or published foreign patent application listed in an information disclosure statement must be identified by the country or patent office which issued the patent or published the application, an appropriate document number, and the publication date indicated on the patent or published application.

NOTE: 37 C.F.R. 1.98(b):

(5)

WARNING:

Each publication listed in an information disclosure statement must be identified by publisher, author (fi any), title, relevant pages of the publication, date, and place of publication.

No extension of time can be had under 37 C.F.R. § 1.36 (a) or (b) for filing an IDS. 37 C.F.R. § 1.97(f).

NOTE: The "filing date of a national application" under 37 C.F.R. J. 97(b) has two possible meanings. Where the filing is a direct one to the United States Patient & Trademark office, the filing is defined in 37 C.F.R. J. 33(b) as "the date on which (1) A specification containing a description pursuant to § 1.71 and at least one claim pursuant of § 1.75; and (2) any drowing required by § 1.81(o), are filed in the Flatent and Trademark Office in the man of the actual inventor or inventors as required by § 1.91." 37 C.F.R. 1.97(b)(1). On the other hand, an international application that enters the national stage occurs when the applicant has filed the documents of the stage of the following (1) the national stage occurs when the applicant has filed the documents the filing of the following: (1) the national fee; (2) a copy of the international application, unless already sets by the International Bureau, and an English translation iffiled in another language; (3) amendment under PCT Article 19, with a translation into English fy finde in another language; (4) an oath or declaration, and (3) a translation into English fy finde in another language; (4) an oath or declaration, and 1,70(b)(2).

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. 1.97(b).

- NOTE: "No certification or fee is due when the filing is made within the above time period. It is advisable to ensure that no Office action has been mailed if the disclosure statement is delayed until after three months from filing."
- NOTE: "An information disclosure statement will be considered to have been filed on the day it was received in the Office, or on an earlier date of a maling if accompanied by a properly executed certificate of mailing under 37 C.F.R. 1.8. or Express Mail certificate under 37 C.F.R. 1.10. An office action is mailed on the date indicated in the Office action." Notice of April 20, 1992 (1138 Oct 374.1, 39).
- NOTE: "The term 'national application' includes continuing applications (continuations, divisions, continuations-in-part) so three-months will be measured from the actual filing date of an application as opposed [sic] to the effective date of a continuing application." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

- NOTE: "An action on the merits means an action which treats the patentality of the claims in an application, as opposed to only formal or procedural requirements. An action on the merits would, for example, contain a rejection or indication of allowability of a claim or claims rather than just a restriction requirements (37 C.F.R. 1.1642) or just a requirement for additional fees to have a claim considered (37 C.F.R. 1.1649). Thus, if an application was filed on Jan. I and the first Office action on the merits was not malied until six months later on July I, the examiner would be required to consider any proper information disclosure statement filed prior to July I. "Notice of April 20, 1992 (1138 O.G. 37-41, 39).
- WARNING: "A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as falling to present good and sufficient reasons, since 37 C.F.R. 1.97 provides adequate recourse for the timely submission of prior an for consideration by the examiner." Notice of July 6, 1992 (1141 O.G. 53).

If a fee is required, please charge deposit account 12-0425.

Reg. No. 33,778

Tel. No.: (212)708-1935

Customer No.: 00140

SIGNATURE OF PRACTITIONER

JANET I. CORD

(type or print name of practitioner)

LADAS & PARRY LLP P.O. Address

26 WEST 61ST STREET NEW YORK, NEW YORK 10023

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AN 9. 6 2007 In he application of: GERRIT DIRK KEIZER, et al Statal No.: 10/568,633

Group No.: 1645 Examiner: N/A

METHOD FOR DETECTING MULTIPLE ANALYTES

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

We draw the attention of the Examiner to the attached reference which is also listed on

the attached Form PTO-1449.

Respectfully submitted,

JÁNET I. CORD LADAS & PARRY LLP 26 WEST 61ST STREET NEW YORK, NEW YORK 10023 REG.NO.31.053(212)708-1935

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

37 C.F.R. 1.10*

with sufficient postage as first class mail.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Date: January 23, 2007

5.59.....

Janet I. Cord
(type or print name of person certifying)

*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing, 37 C.F.R. 1.10(b).

[&]quot;Since the filing of correspondence under § 1.10 without the Express Mail mailing labet thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Ped. Reg. 56, 439, at 56,442.

						Sheet 1	_ of _1	
FORM DTQ.1	449 U.S.DEP	ARTMENT OF COM	OF COMMERCE		DOCKET NO.	SERIAL NO.		
		AND TRADEMARK OFFICE		U 016156-3		10/568,633		
JAN 9.6 2001 WINFORMATION DISCLOSURE					APPLICANT			
					Gerrit Dirk KEIZER, et al.			
STEW & TRADES	(Use several sh	eets if necessary)		FILING DATE		GROUP		
GTHADE					ber 26, 2006	T645 1641		
		U.S. P	ATENT DO	CUMENTS	3			
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DAT	E	NAME		FILING DATE IF APPROPRIATE	
	AA							
	AB							
	AC							
	AD							
	AE							
	AF	1						
	AG							
	АН							
	AI							
	AJ							
	AK							
		FOREIGN	N PATENT I	OCUMEN	NTS			
	D0CUMENT					TRANSLATION		
		NUMBER	DATE		COUNTRY	YES	NO	
	AL							
	AM							
	AN							
	AO							
	AP							
	ОТ	HER ART (Includi	ng Author, T	itle, Date,	Pertinent Dates, Etc.)			
/C.C./	Aranha-Creado, H., et al. "Clearance of Murine Leukaemia Virus from Monoclonal Antibody AR Solutions by a Hydrophilie PVDF Microporous Membrane Filter "Biologicals Vol. 26, No. 2 (1998) pp 167-172							
	AS							

ΑT

EXAMINER EXAMINER: /Christopher Chin/

DATE CONSIDERED 06/14/2008

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.